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1.1 DNA methyl lesions 
DNA methylation is an important epigenetic mark modulating many developmental and potentially 
pathological processes. Changes in DNA methylation are often observed in cancer and, cytosine methylation in 
particular, can be mediated enzymatically, resulting in e.g. 5-methylcytosine (5mC) or chemically, resulting in 
e.g. 3-methylcytosine (3mC)[1, 2]. If base pairing is affected by methylation as it is by 3mC, it can lead to methyl 
lesions which, if refractory to repair, can add to the mutational burden of affected cells. Here, we explore 
some underappreciated properties of 3mC in cancer.  
Arising from non-enzymatic methylation by endogenous or exogenous methyl donors, chemically mediated 
methyl lesions can have disruptive effects on local DNA functionality[3]. In non-malignant cells, it can be 
expected that DNA repair pathways are intact and that any lesions will be repaired or, if the damage confers 
no selective growth advantage and is potentially lethal to the cell, programmed cell death (apoptotic) 
pathways will be activated. Conversely, in cancer where DNA repair mechanisms and apoptotic pathways are 
compromised due to somatic mutations, these methyl lesions and their effects on DNA are likely to persist.  
The best known and investigated example of chemically mediated methyl lesions is O6-methylguanine (6mG), a 
major product of methylating compounds and chemotherapeutic drugs such as temozolomide[4]. Other, more 
“minor”, methyl lesions (including 3mC), with their own specific repair enzymes can also be formed but are 
currently far less studied.  
The repair enzymes of 3mC lesions, AlkB homologs (ABH) and in particular ABH2 and ABH3, have garnered 
recent interest based on observations made in vitro of their involvement in chemotherapeutic resistance in 
several cancer types, including glioblastoma, non-small cell lung cancer, bladder and prostate cancer[5, 6]. 3mC 
may therefore serve as a surrogate marker for ABH activity as, while in normal cells, ABH2 and ABH3 are 
ubiquitously expressed, the transcription levels of these enzymes can be decreased with TP53 pathway 
activation[5]. Considering that TP53 is often mutated in cancer, inactivating the TP53 damage response 
pathway and thereby affecting cellular ability to alter ABH levels, it is tempting to speculate on the 
downstream consequences. It is conceivable that with impaired repair activity, the level of 3mC is likely to rise, 
generating changes in local DNA structure, and thus increased local mutagenicity and thereby contributing to 
the additional mutational burden and/or increasing cellular fitness. In this context, 3mC may be an example of 
the epigenotype driving the genotype. 
This leads us to question whether minor epigenetic lesions have been overlooked due to their lower rate of 
formation resulting in an underappreciation of their impact on cancer development and progression?  
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1.2 3mC levels  
In RNA, 3mC can be catalysed both enzymatically (e.g. in tRNA) and chemically, but in DNA 3mC can only be 
formed chemically via non-enzyme catalysed direct methyl group transfer[7]. Direct transfer can occur either 
from endogenous S-adenosyl methionine (SAM), the primary methyl donor for enzymatic methylation such as 
for 5mC in DNA; or by exogenous methylating compounds such as temozolomide, tobacco-specific 
nitrosamines (a major group of carcinogens found in tobacco smoke) or methyl methanesulphonate (MMS)[2, 
8]. Direct chemical formation of 3mC by SAM however, occurs at a rate about 2000 times slower than by other 
chemical compounds like those mentioned above[9]. It is interesting to note that when the magnesium co-
factor for SAM is chelated with ETDA in vitro, 3mC formation is inhibited, despite an overall increase in methyl 
products, highlighting the specificity in 3mC generation[10].  
Chemically formed 3mC preferentially occurs in single-stranded DNA (ssDNA) and RNA. Direct methyl donation 
occurs via “backside attack” requiring that the lone electron pair of N3 in cytosine to attack the methyl group 
directly opposite to the adjacent atom in the methyl-donating molecule leaving group. In double-stranded 
DNA (dsDNA), the base pairing guanine sterically hinders the rate of 3mC formation as the guanine occupies 
the space where the methylating compound needs to be[11]. Therefore, in cells with higher transcription rates, 
the opportunities for 3mC formation are higher due to a higher proportion of DNA existing in a single stranded 
state. This transcription-dependant formation rate possibly explains ABH2 and ABH3’s DNA transcription-
based activity regulation. 
1.3 3mC effects on transcription 
The effect of 3mC on transcription is dependent on polymerase fidelity. Higher fidelity polymerases, such as 
DNA polymerase delta are halted upon encountering 3mC. Lower fidelity polymerases such as bypass 
polymerases nel, kappa or RNA polymerases tend to misincorporate bases. E. coli RNA polymerase was shown 
to misincorporate bases at a ten-fold higher rate than DNA polymerase I which is more often halted when 
encountering 3mC[11-13]. It was shown that changing the co-factor of DNA polymerase I in vitro from 
magnesium to manganese caused an increase in misincorporation of bases and a switch in the downstream 
effect of 3mC from cytostatic to mutagenic, an effect similarly observed between the X and Y families of 
human DNA polymerases[2, 14].  
AlkB+ SOS- E. coli treated with MMS showed little (<2%) appreciable mutations due to 3mC, compared to 30% 
mutagenicity in AlkB- SOS- E. coli. In AlkB- SOS+ cells, mutagenicity rose to 70%, with a concordant decrease in 
cytotoxicity due a lack of direct repair and increased lesion bypass using DNA polymerase V. The replicative E. 
coli DNA polymerase III holoenzyme showed a higher mutation generation rate compared to DNA polymerase 
I, likely due to the proofreading capability of DNA polymerase I causing replicative arrest and allowing for 
removal of 3mC as the rate became nearly equal when the proofreading capability was removed[10]. 
1.4 3mC as a biomarker 
Chemotherapeutic regimes do not necessarily include methylating compounds however inducers of double-
stranded DNA breaks such as platinum compounds (e.g. cisplatin) and topoisomerase inhibitors (e.g. 
ifosfamide) are often included. As previously seen in E. coli, the generation of strand breaks and pausing of 
replication for repair allows DNA to be in single stranded form for longer and thus may indirectly allow 
increased generation of 3mC and additional time to enact effects within the cell, particularly when the repair 
pathways have been impaired[15, 16].  
Knockdown studies of ABH2 and ABH3 suggested that decreased levels of ABH increased sensitivity to 
chemotherapeutics[5, 6]. If the levels of ABH2 and ABH3 are linked to resistance as previously suggested then a 
higher than normal level of ABH2 or ABH3 would provide increased chemotherapeutic resistance. As such, due 
to ABH being the main method of repair for 3mC, assuming a basal level of 3mC, a lower than expected level of 
3mC would indicate presence of increased resistance. If observed in untreated patients, this may predict a 
decreased response to chemotherapy and therefore could act as a surrogate predictive biomarker for 
chemotherapeutic response allowing a more personalised therapeutic regimen.  
1.5 Outlook 
There are many open questions that will determine the future importance and interest in 3mC over and above 
its current potential as cancer-specific biomarker. For example, kataegis mutation signatures (hypermutability 
localised to small genomic regions) have recently gained interest for understanding cancer development and 
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potentially helping to guide prevention and therapy but the underlying mechanisms are poorly understood. 
Such signatures have been shown to be significantly associated with patients treated with alkylating agents in 
glioblastoma multiforme, mutagens within tobacco smoke in lung cancer and altered DNA maintenance and 
repair in several cancers[17], which are all hallmarks of increased 3mC formation. While DNA strand breaks have 
been shown to be a major driver of kataegis signatures[18], it is possible that 3mC may contribute as well and 
thus be an example of an epigenotype driven genotype. Analysis of kataegis signature samples for 3mC should 
clarify this hypothesis.  
In addition, 3mC may even have broader implications. As chemically mediated methylation predates enzymatic 
methylation, it will be interesting to explore if during evolution, any organism has ever harnessed chemical 
DNA methylation such as 3mC for regulating biological processes akin to processes regulated by 5mC. Prime 
candidates would be extremophiles particularly those that have adapted to life under high levels of alkylating 
compounds, the largest group of chemicals interacting with DNA and frequently part of chemotherapy in the 
treatment of cancer. An important first step towards this exploration will be to develop quantitative 
sequencing-based chemistries for the detection of 3mC in DNA and to identify proteins that specifically bind to 
3mC besides AlkB and its homologs.  
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